Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne C Mirabella

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Chromosoma|July 20, 2015
Chromatin deregulation in diseaseAnne C Mirabella, Benjamin M Foster, Till Bartke
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2013
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancerLuca Magnani, Alexander Stoeck, Xiaoyang Zhang, et al.
Analytical Biochemistry|February 4, 2014
Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activityOwen M Wilkins, Sondra L Downey, Emily S Weyburne, et al.
Chemistry & Biology|May 26, 2011
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomibAnne C Mirabella, Alexandre A Pletnev, Sondra L Downey, et al.
Haematologica|June 13, 2015
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cellsMarianne Kraus, Juergen Bader, Paul P Geurink, et al.
Journal of Medicinal Chemistry|January 17, 2013
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sitesPaul P Geurink, Wouter A van der Linden, Anne C Mirabella, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Chromosoma|July 20, 2015
Chromatin deregulation in diseaseAnne C Mirabella, Benjamin M Foster, Till Bartke
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2013
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancerLuca Magnani, Alexander Stoeck, Xiaoyang Zhang, et al.
Analytical Biochemistry|February 4, 2014
Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activityOwen M Wilkins, Sondra L Downey, Emily S Weyburne, et al.
Chemistry & Biology|May 26, 2011
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomibAnne C Mirabella, Alexandre A Pletnev, Sondra L Downey, et al.
Haematologica|June 13, 2015
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cellsMarianne Kraus, Juergen Bader, Paul P Geurink, et al.
Journal of Medicinal Chemistry|January 17, 2013
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sitesPaul P Geurink, Wouter A van der Linden, Anne C Mirabella, et al.
Pageof 1